Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials

R. Iacovelli, A. Altavilla, G. Procopio, S. Bracarda, M. Santoni, S. Cascinu, E. Cortesi

Research output: Contribution to journalArticle

Abstract

Background:About 20% of patients with prostate cancer have an ECOG performance status (PS) ≥2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies.Results:A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR=0.69; 95% CI: 0.63-0.76; P

Original languageEnglish
Pages (from-to)323-327
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume16
Issue number4
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Abiraterone acetate
  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Enzalutamide
  • Performance status
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials'. Together they form a unique fingerprint.

  • Cite this